A Study to Determine if the Drug Gemfibrozil Changes How Oxygen is Transported in Blood

Overview

About this study

The goal of this study is to determine the potential role of gemfibrozil in studying how oxygen binding to hemoglobin affects the acute response to both normoxic and hyperoxic (breathing gas with high O2) exercise in humans. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Generally healthy male and female non-smoking participants
  • 18-40 years old with no significant metabolic, cardiovascular, pulmonary, hepatic, gastrointestinal, or renal disease and no contraindications to exercise
  • The participants will be non-obese  

Exclusion Criteria:

  • Those taking medications that might influence the cardiovascular or respiratory responses to exercise will also be excluded (e.g. beta blockers and some other anti-hypertensives along with anti-asthma drugs).  

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Chad Wiggins, Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions